‘Game-changing’ treatment gets green light for HFpEF

Leading cardiologist provides an update on the clinical management of heart failure with preserved ejection fraction
1
15 February 2023
Save
Professor David Kaye

This content has been independently produced by ADG, made possible through sponsorship from Boehringer Ingelheim and Eli Lilly.

Heart failure with preserved ejection fraction (HFpEF) affects more than half of patients with heart failure yet it is notoriously difficult to treat. In this Q&A, Professor David Kaye (pictured), director of cardiology at Melbourne’s Alfred Hospital, talks to ADG about a ‘game-changing’ treatment that’s been given the green light for HFpEF.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .